DUBLIN, Calif., June 13 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced at the 13th Congress of theEuropean Hematology Association (EHA) in Copenhagen, Denmark, that its lead,oral PIM kinase inhibitor, SGI-1776, causes tumor regression in acutemyologenous leukemia (AML) xenograft models (abstract #744).
In a poster presentation entitled "A potent small molecule PIM kinaseinhibitor with in vivo oral availability and activity in cell lines fromhematological malignancies," Dr. Gregory Berk, SuperGen's Chief MedicalOfficer, detailed how scientists used SuperGen's CLIMB(TM) technology to builda model that allowed for the creation of small molecule PIM kinase inhibitors.SGI-1776 was identified as an orally available, potent and selective inhibitorof the PIM kinases. SGI-1776 induces cell cycle arrest, dose dependentapoptosis and a reduction in phospho-BAD levels in leukemia and lymphoma celllines. Phospho-BAD is a direct substrate for PIM, and may serve as a usefulin vivo biomarker for future clinical trials. Most notably, SGI-1776 inducedsignificant tumor regression in MOLM-13 and MV-4-11 (AML) xenograft models.
"Our PIM kinase inhibitor, SGI-1776, has the potential to be an effectivetreatment for AML and other malignancies that over-express PIM kinase," saidDr. James Manuso, SuperGen's President and Chief Executive Officer. "The dataalso provide support for the use of our CLIMB(TM) technology to identify andrapidly advance candidates into the clinic. We plan to initiate Phase 1clinical trials with SGI-1776 in solid tumors and leukemias later this year.SGI-1776 may become the first drug in this class of inhibitors to enter theclinic."
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factorsthat might cause the company's results to differ materially from thoseexpressed or implied by such forward-looking statements include, but are notlimited to, the ability to discover, develop and move target compounds intoclinical development and other risks and uncertainties detailed from time totime in the company's filings with the Securities and Exchange Commissionincluding its most recently filed Form 10-Q and 10-K. SuperGen, Inc.undertakes no duty to update any of these forward-looking statements toconform them to actual results.SuperGen's schedule of presentations at EHA is as follows: Date Time (PDT) Abstract # and Title Friday, June 13 8:45 a.m.-10 a.m. #744 - A potent small molecule PIM kinase inhibitor with in vivo oral availability and activity in cell lines from hematological malignancies Sunday, June 15 1:30 a.m.-2:45 a.m. #741 - SGI-1252: A pot